| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Asunercept | CAN-008; APG-101 | Phase 2 Clinical | Apogenix Gmbh | Coronavirus Disease 2019 (COVID-19); Eye Diseases; Glioblastoma; Hematologic Neoplasms; Myelodysplastic Syndromes; Skin Diseases; Solid tumours | Details |
| Xelafaslatide | ONL-1204 | Phase 2 Clinical | Onl Therapeutics | Geographic Atrophy; Glaucoma, Open-Angle; Macular Degeneration; Retinal Detachment | Details |
| M3T01 | M3T01 | Phase 1 Clinical | Providence Health & Services | Solid tumours | Details |